Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotyping drug disposition in oncology.

Cancer treatment reviews - 1 Oct 2012

Opdam Frans L, Gelderblom Hans, Guchelaar Henk-Jan

Abstract excerpt

Efficacy and toxicity of anticancer agents are highly variable between patients and variation in drug disposition is thought to be an important determinant. Genetics, physiology, and environment all are underlying factors contributing to this variation. Phenotyping drug metabolizing enzymes and drug transporters by using in vivo probes is a method that can be used to individualize drug therapy. This review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 Enzyme System
Share to Antineoplastic Agents
Share to Biological Transport

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Inactivation, Metabolic

Share to Membrane Transport Proteins

Share to Neoplasms

Share to Phenotype

Source

Identifiers

PMID: 22226243
DOI: 10.1016/j.ctrv.2011.12.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotyping drug disposition in oncology.PMID 22226243Read ↗

Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapySemantic proximity Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Semantic proximity Read ↗

Pharmacogenomics in cancer therapy: is host genome variability important?Semantic proximity Read ↗

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Semantic proximity Read ↗

Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Semantic proximity Read ↗

Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug DevelopmentSemantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

Pharmacogenomics: a tool for improving cancer chemotherapy.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Semantic proximity Read ↗

The role of drug-metabolising enzymes in clinical responses to chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.